Pfizer and Eli Lilly CEOs Named Among TIME100 Health's Most Influential People in Healthcare 2024

May 13, 2024 09:25 CST Updated 09:26

Novo Nordisk

Insulin Developer and Manufacturer

Pfizer

Pharmaceutical R&D Developer

Eli Lilly

Global Pharmaceutical R&D and Production Company

▲May 30-31The 8th Guangzhou Biomedical Innovators Summit
Scan the code to register immediately

Note: This article does not constitute any investment opinions or recommendations., subject to official/company announcements; this article only introduces drugs related to medical health and does not recommend treatment plans (if involved), and does not represent the platform's position. Any article reprint requires authorization.

Recently, TIME magazine unveiled the 2024 list of the 100 most influential figures in healthcare (TIME100 Health). TIME stated that this year’s list is composed of leaders from various industries (scientists, doctors, educators, policymakers, etc.), inspiring confidence that the world is moving toward better health and is currently in a golden age of achievement and transformation.

TIME1 202400 HealthHighlights of the List

The 2024 TIME100 Health List includesPharmaceutical IndustryAmong the CEOs, founders, and co-founders, including:Novo NordiskLars Fruergaard Jørgensen of Novo Nordisk A/S,PfizerPfizer's Albert Bourla andEli Lilly's Dave Ricks, etc. Also included are medical scientistsZiyad Al-Aly、Avindra Nath, David Baker, et al.

Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen joined Novo Nordisk in 1992 and has been serving as the company's CEO since January 2017. In 2023, bolstered by Novo Nordisk's strong performance, Lars Fruergaard Jørgensen received a 13% salary increase, bringing his compensation to 68.2 million Danish kroner (approximately $9.9163 million).

Albert Bourla joined Pfizer in 1993, began serving as CEO in January 2019, and has been Chairman of the Board since January 2020.Bourla completed Pfizer's $43 billion acquisition of Seagen in 2023 and secured a record nine approvals for Pfizer in an approval-filled year, includingRespiratory Syncytial VirusTwo Approvals for the (RSV) Vaccine Abrysvo.

Dave Ricks

Dave Ricks is the Chairman of the Board and Chief Executive Officer of Eli Lilly and Company. He has served as Chief Executive Officer since January 2017 and was elected Chairman of the Board in June 2017.

Dave has over 20 years of work experience at Eli Lilly and Company. From 2012 to 2016, he served as President of Eli Lilly's Biomedicines division. Prior to that, he was President of Eli Lilly's largest subsidiary, Eli Lilly USA, from 2009 to 2012. From 2008 to 2009, he served as President and General Manager of Eli Lilly China, overseeing operations in this fastest-growing emerging market globally.

Dr. Ziyad Al-Aly

Dr. Ziyad Al-Aly is a clinical epidemiologist at the Washington University School of Medicine. Since 2020, his research team has published nearly 20 studies on post-COVID conditions (Long COVID), aiding in understanding the various long-term effects of COVID-19. He stated that the next steps will focus on researching potential Long COVID therapies and determining whether SARS-CoV-2 has unique characteristics in causing long-term damage.

Dr. Nath

Dr. Nath is a renowned physician-scientist specializing in neuroimmunology and neurovirology. His research focuses on the clinical manifestations, pathophysiology, and treatment of emerging neurological infections, with an emphasis onHuman Immunodeficiency Virus(HIV) infection. Over the past two decades, Dr. Nath has become an internationally recognized expert in this field, traveling the world to study patients with Ebola, Zika virus, and nodding syndrome, and conducting extensive research on how viruses affect the brain and nervous system.

In recent years, Dr. Nath has garnered global attention for his timely work on how COVID-19 affects the brain, includingVascular Damage in the Brains of Patients Who Died from Severe COVID-19、Discovery of Virus-Induced Immune ResponsesAndResearch on Long COVID Characterization。This year, he led a landmark clinical study focusing on chronic, debilitatingMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The studyReveals Previously Unknown Biological Mechanisms, these mechanisms can be for ME /CFSProvide information for the diagnosis and future treatment of other post-infection diseases. At NINDS, Dr. Nath continues to study neurological infections and leads clinical trials testing new therapies.

David Baker

With the advent of artificial intelligence (AI) tools like AlphaFold, protein structure prediction and design have become one of the earliest fields to benefit. Groundbreaking advancements in this area are emerging at a "rapidly evolving" pace. Among these, Professor David Baker's team at the University of Washington, a pioneer in protein design, has repeatedly revolutionized the rules of protein design — from developing tools that can design novel proteins in just one second to creating antibodies capable of targeting any protein.Based on his team's research, he has co-founded at least 17 cutting-edge companies.Among them, those dedicated to using artificial intelligence to redefine the methods of drug discovery and developmentXaira TherapeuticsOfficially launched recently, securing initial funding exceeding 1 billion US dollars.

References:

https://time.com/collection/time100-health/

Copyright statement: This article is reproduced from the Biopharmaceutical Era,Media or individuals who do not wish to be reproduced can contact us, and we will delete it immediately.

Recommended Activities

May • 8th Greater Bay Area Biomedical Innovators Summit

Keywords: Small Molecules, XDC, Peptides, and GLP-1 Hot Topics, 80+ Industry Experts (Click the Image Below for Details)

▼

[About PharmaCircle]

PharmCube PRHub aims to assist biopharmaceutical technology enterprises in brand promotion and business development services. It develops systematic solutions based on clients' real needs, using "translation-simplification-contextualization" to make clients' brand information easily understood by the public. Meanwhile, with a reach of over 1 million vertical users across traffic channels, it achieves cooperation goals, helping partners complete closed-loop marketing services from branding to business. We have successfully organized dozens of offline biopharmaceutical R&D conferences with 1,000 attendees, covering areas such as small-molecule new drugs, large-molecule new drugs, modified new drugs, and BD cross-border transactions, serving more than a hundred listed/unicorn/biotech/pharmaceutical companies.